Table 2.

Clinical trials to maintain TFR in addition to TKI

TIGER nilotinib ± peg-IFNA2b (phase 3)	NCT01657604
PETALs nilotinib ± peg-IFNα2a (phase 3)	NCT02201459
IFNA maintenance therapy
TIGER peg-IFNA2b (phase 3)	NCT01657604
ENDURE pegylated-proline-IFNA2b (phase 3)	NCT03117816
Checkpoint inhibitors
ACTIW pioglitazone (phase 1), avelumab (phase 2)	NCT02767063
Dasatinib nivolumab (phase 1B)	NCT02011945
JAK inhibition
Preclinical data
Nilotinib + ruxolitinib phase 1/2	NCT01914484
Nilotinib + ruxolitinib phase 1	NCT02253277
Nilotinib + ruxolitinib phase 1	NCT01702064
ABL-TKI + ruxolitinib phase 2	NCT03610971
ABL-TKI + ruxolitinib phase 2	NCT03654768
BCL-2 inhibition
Preclinical data
Dasatinib ± venetoclax phase 3	NCT02689440
BTK inhibition
Preclinical data